Response to induction chemotherapy by treatment group
. | Group A, G-CSF-/- . | Group B, G-CSF+/- . | Group C, G-CSF-/+ . | Group D, G-CSF+/+ . | Total, Groups A-D . | Groups A + C, G-CSF-/- . | Groups B + D, G-CSF+/. . | Groups A + B, G-CSF./- . | Groups C + D, G-CSF./+ . |
|---|---|---|---|---|---|---|---|---|---|
| No. patients | 182 | 180 | 180 | 180 | 722 | 362 | 360 | 362 | 360 |
| Overall complete response | 89 (48.9) | 94 (52.2) | 87 (48.3) | 116 (64.4) | 386 (53.5) | 176 (48.6) | 210 (58.3) | 183 (50.6) | 203 (56.4) |
| Partial response | 1 (0.5) | 9 (5.0) | 6 (3.3) | 7 (3.9) | 23 (3.2) | 7 (1.1) | 16 (4.4) | 10 (2.7) | 13 (3.6) |
| Resistant disease | 64 (35.1) | 49 (27.2) | 46 (25.5) | 33 (18.4) | 192 (26.6) | 110 (30.3) | 82 (22.7) | 113 (31.2) | 79 (21.9) |
| Early death | 4 (2.2) | 2 (1.1) | 5 (2.8) | 6 (3.3) | 17 (2.3) | 9 (2.5) | 8 (2.2) | 6 (1.7) | 11 (3.1) |
| Death in hypoplasia | 21 (11.5) | 18 (10.0) | 27 (15.0) | 15 (8.3) | 81 (11.2) | 48 (13.3) | 33 (9.2) | 39 (10.8) | 42 (11.7) |
| Unknown/missing data | 3 (1.6) | 8 (4.4) | 9 (5.0) | 3 (1.6) | 23 (3.2) | 12 (3.3) | 11 (3.0) | 11 (3.0) | 12 (3.3) |
. | Group A, G-CSF-/- . | Group B, G-CSF+/- . | Group C, G-CSF-/+ . | Group D, G-CSF+/+ . | Total, Groups A-D . | Groups A + C, G-CSF-/- . | Groups B + D, G-CSF+/. . | Groups A + B, G-CSF./- . | Groups C + D, G-CSF./+ . |
|---|---|---|---|---|---|---|---|---|---|
| No. patients | 182 | 180 | 180 | 180 | 722 | 362 | 360 | 362 | 360 |
| Overall complete response | 89 (48.9) | 94 (52.2) | 87 (48.3) | 116 (64.4) | 386 (53.5) | 176 (48.6) | 210 (58.3) | 183 (50.6) | 203 (56.4) |
| Partial response | 1 (0.5) | 9 (5.0) | 6 (3.3) | 7 (3.9) | 23 (3.2) | 7 (1.1) | 16 (4.4) | 10 (2.7) | 13 (3.6) |
| Resistant disease | 64 (35.1) | 49 (27.2) | 46 (25.5) | 33 (18.4) | 192 (26.6) | 110 (30.3) | 82 (22.7) | 113 (31.2) | 79 (21.9) |
| Early death | 4 (2.2) | 2 (1.1) | 5 (2.8) | 6 (3.3) | 17 (2.3) | 9 (2.5) | 8 (2.2) | 6 (1.7) | 11 (3.1) |
| Death in hypoplasia | 21 (11.5) | 18 (10.0) | 27 (15.0) | 15 (8.3) | 81 (11.2) | 48 (13.3) | 33 (9.2) | 39 (10.8) | 42 (11.7) |
| Unknown/missing data | 3 (1.6) | 8 (4.4) | 9 (5.0) | 3 (1.6) | 23 (3.2) | 12 (3.3) | 11 (3.0) | 11 (3.0) | 12 (3.3) |
Results are presented as absolute numbers, with the percentages in parentheses. -/- indicates not administered; +/-, administered on days 1 to 7; -/+, administered on days 8 to 28; +/+, administered on days 1 to 28; -/., not administered on days 1 to 7; +/., administered on days 1 to 7;./-, not administered on days 8 to 28; and./+, administered on days 8 to 28.